NEO Tingkat bathi miturut bathi reged NeoGenomics Inc

Historically, NeoGenomics, Inc. (NEO) has optimized costs by centralizing laboratory hubs. The gross margin ratio demonstrates current profitability, where the value of 42.60 characterizes this level. Looking ahead, steady demand for oncology tests guarantees a stable cash flow, although high leverage and pressure from insurance tariffs create certain financial risks for the business.
Rincian metrik komprehensif lan analitis NeoGenomics, Inc. (NEO)

For an investor in NeoGenomics, Inc. (NEO), this metric serves as a gauge of efficiency in managing direct costs, including expensive express logistics for climate-controlled biomaterials. By analyzing the gross margin distribution, one can assess the portion of revenue remaining after the cost of services, which determines the business's ability to scale profits and maintain strong fundamental stability within the oncology diagnostics sector.